NASDAQ:UNCY Unicycive Therapeutics Q1 2025 Earnings Results & Report $3.59 -0.11 (-2.97%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$3.74 +0.15 (+4.07%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Unicycive Therapeutics beat analyst earnings expectations in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$0.50 versus the -$1.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 14, 2025TimeBefore Market OpensConference Call8:00 AM ET Unicycive Therapeutics EPS ResultsActual EPS-$0.50Consensus EPS -$1.40Beat/MissBeat by +$0.90One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersUnicycive Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsUnicycive Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Unicycive Therapeutics Q1 2025 Earnings FAQ Did Unicycive Therapeutics beat earnings estimates for Q1 2025? Unicycive Therapeutics (NASDAQ:UNCY) reported earnings of -$0.50 per share for Q1 2025, beating the consensus estimate of -$1.40. The report was announced on Wednesday, May 14, 2025. When is Unicycive Therapeutics' next earnings date? Unicycive Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Unicycive Therapeutics on the company's earnings history page. Unicycive Therapeutics Earnings HeadlinesSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCYOctober 15 at 10:15 AM | prnewswire.comBronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmOctober 15 at 10:00 AM | globenewswire.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 16 at 1:00 AM | Investors Alley (Ad)Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their RightsOctober 14 at 7:31 PM | globenewswire.comUNICYCIVE DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYOctober 14 at 7:15 PM | globenewswire.comDeadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitOctober 14 at 2:40 PM | globenewswire.comSee More Unicycive Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email. Email Address About Unicycive TherapeuticsUnicycive Therapeutics (NASDAQ:UNCY) (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease. The company’s primary focus is hyperphosphatemia, a condition in which phosphate levels become abnormally high in patients with chronic kidney disease, particularly those receiving dialysis. Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream. The company is developing OLC as a potential treatment option for patients with chronic kidney disease who require dialysis and need ongoing phosphate management. The company’s activities are primarily focused on advancing OLC through clinical development and regulatory processes, initially in the United States. Unicycive is headquartered in the United States and is led by Chief Executive Officer Shalabh Gupta, M.D.View Unicycive Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
